Cognito Therapeutics develops neurotechnology therapies to treat neurodegenerative diseases by stimulating specific brain activity patterns.
Cognito Therapeutics has raised $105.0M in total funding. The most recent round was Series C. The last funding was announced in March 2026.
Cognito Therapeutics's investors include Apollo Health Ventures, IAG Capital Partners, OpAmp Capital, New Vintage Partners, Alzheimer's Drug Discovery Foundation.
Cognito Therapeutics is headquartered in Cambridge, United States.
Cognito Therapeutics develops neurotechnology therapies to treat neurodegenerative diseases by stimulating specific brain activity patterns.
Cognito Therapeutics is at the Series C stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Cognito Therapeutics — Funding & Investors." VCBacked, March 5, 2026, https://www.vcbacked.co/company/cognito-therapeutics. Accessed September 30, 2026.
VCBacked. (2026). Cognito Therapeutics — Funding & Investors. Retrieved September 30, 2026, from https://www.vcbacked.co/company/cognito-therapeutics
{{cite web |title=Cognito Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/cognito-therapeutics |website=VCBacked |access-date=September 30, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated